Lupin Digital Health's Lyfe Platform Granted Class C Medical Device License

This development underscores a pivotal advancement in post-discharge integrated care, highlighting the potential of evidence-based digital therapeutics solutions to revolutionize patient care.

Lupin Digital Health, a leading player in the digital health landscape, has achieved a significant milestone with its Lyfe platform, securing approval as a Class C Medical Device from the Central Drugs Standard Control Organization (CDSCO). 

This development underscores a pivotal advancement in post-discharge integrated care, highlighting the potential of evidence-based digital therapeutics solutions to revolutionize patient care.

Reaffirming Commitment to Quality & Safety

Undergoing a rigorous application, review, and on-site audit process, the Class C Medical Device license validates the effectiveness of Lupin Digital Health's Lyfe platform. 

Sharing insights, Rajeev Sibal, President - India Region Formulations, Lupin, said, "This approval reaffirms our dedication to excellence in cardiac care. We are proud to be at the forefront of digital therapeutics in India, signifying our commitment to supporting cardiologists with patient-centric solutions and improving cardiovascular outcomes."

Empowering Patients with Remote Cardiac Rehabilitation

The Lyfe platform emerges as India's first clinically proven remote cardiac rehabilitation program designed to enhance heart health and quality of life. By offering tailored, accessible solutions in the comfort of patients' homes, Lyfe empowers individuals to manage their heart health confidently.

Commenting on the same, Sidharth Srinivasan, CEO, Lupin Digital Health, said, "Securing the Class C Medical Device license for Lyfe is a significant achievement. It validates Lyfe as a best-in-class platform to support millions of cardiac patients in India. This recognition will encourage more cardiologists, hospitals, and insurers to adopt remote cardiac rehabilitation for improved patient health outcomes."

Expanding Reach & Impact

Trusted by over 700 cardiologists and serving patients across 280 districts in India, Lyfe provides cardiovascular patients who have undergone events like angioplasty, bypass surgery, and heart failure with a better way to manage and recover from their condition. 

The platform's reach signifies its potential to impact the healthcare landscape substantially, offering accessible solutions to a wide demographic.

Other Noteworthy Developments

In addition to the Class C Medical Device license for the Lyfe platform, Lupin Limited, the parent company, has launched Bromfenac Ophthalmic Solution, 0.075%, following the United States Food and Drug Administration (US FDA) approval. This solution serves as the generic counterpart to BromSite Ophthalmic Solution, 0.075%, produced by Sun Pharmaceutical Industries Limited, catering to postoperative inflammation and preventing ocular pain among patients undergoing cataract surgery.

Furthermore, Lupin Digital Health has partnered with the American College of Cardiology (ACC) to launch the first-ever digital therapeutics certificate for cardiologists. This initiative recognizes cardiologists' commitment to innovation and patient-centered healthcare by adopting Lupin's Remote Cardiac Rehab and Digital Heart Failure clinic solutions.

Last year, Lupin introduced several patient engagement programs in the digital health space. 'Humrahi,' a patient support program, focuses on helping patients with diabetes management, while 'Jeet' promotes heart health by offering cost-effective medical solutions, disease counseling, medication reminders, and lifestyle guidance.